Calculation of the cost-effectiveness
 of subcutaneous administration
 of trastuzumab

Abstract

Rational selection of medicines with an assessment of
 their pharmacoeconomic effectiveness is the most effective
 way to ensure safe and efficient treatment and economical
 use of budget funds allocated for drug therapy, as well as to
 reduce the time of hospitalization and treatment of patients.
 The purpose of the research was to evaluate the pharmacoeconomic effectiveness of using the subcutaneous and
 intravenous forms of drug Trastuzumab.
 Research tasks:
 1. Estimate costs when using subcutaneous trastuzumab in an outpatient chemotherapy room (OCR).
 2. Estimate costs when using intravenous trastuzumab
 in a day patient department (DPD)
 3. Estimate costs when using intravenous trastuzumab
 in a round-the-clock hospital
 Results: The paper presents the pharmacoeconomic
 analysis of targeted therapy with trastuzumab in two forms
 for intravenous (IV) administration and trastuzumab emtansine for subcutaneous (SC) administration in breast cancer
 by cost minimization method.
 The costs include the cost of used drugs according to the
 price-list of the unified national distributor SK Pharmacia as
 of January 1, 2018.
 At comparable efficacy and toxicity, the estimated
 cost-effectiveness of trastuzumab per 100 patients per year
 is KZT16,939,600 ($50,972) for SC administration in OCR and
 IV administration in DPD vs. KZT41,783,200 ($125,728) for SC
 administration in OCR and IV administration in a round-theclock hospital.